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Dendritic cells (DCs), important early targets of Ebola virus (EBOV) infection in vivo, are activated by Ebola virus-like particles (VLPs). To
better understand this phenomenon, we have systematically assessed the response of DCs to VLPs of different compositions. VLPs containing the
viral matrix protein (VP40) and the viral glycoprotein (GP), were found to induce a proinflammatory response highly similar to a prototypical DC
activator, LPS. This response included the production of several proinflammatory cytokines, activation of numerous transcription factors including
NF-kappaB, the functional importance of which was demonstrated by employing inhibitors of NF-kappaB activation, and activation of ERK1/2
MAP kinase. In contrast, VLPs constituted with a mutant GP lacking the heavily glycosylated mucin domain showed impaired NF-kappaB and
Erk activation and induced less DC cytokine production. We conclude that the GP mucin domain is required for VLPs to stimulate human
dendritic cells through NF-kappaB and MAPK signaling pathways.
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Marburg and Ebola viruses are members of the family Fi-
loviridae and are the etiologic agents of severe hemorrhagic
fever in infected humans. The recent outbreak of Marburg
hemorrhagic fever in Angola, West Africa that caused over 200
deaths with a mortality rate approximating 90% underscores the
severity of filovirus infection. Ebola virus (EBOV) infections
are also associated with a high mortality rate that ranges from
40% to 90% (Mahanty and Bray, 2004). Although human
infections have occurred sporadically, the extreme virulence of
these viruses magnifies their importance as emerging pathogens
and potential bioweapons.
Infection with the Zaire EBOV causes a rapid hemorrhagic
fever that can result in death within the second week after the
onset of symptoms (Mahanty and Bray, 2004). Several
observations suggest an association between a nonfatal outcome
after filovirus infection and the development of an effective
adaptive immune response. For example, fatal cases of EBOV⁎ Corresponding author. Fax: +1 212 534 1684.
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doi:10.1016/j.virol.2007.03.020hemorrhagic fever (EHF) show signs of an impaired immune
response (Bray and Geisbert, 2005; Hoenen et al., 2006),
lacking the development of a cellular immune response
(Sanchez et al., 2004) and in comparison with nonfatal cases,
demonstrating little or no circulating antibodies against the
virus (Baize et al., 1999). Thus, a rapid and effective adaptive
immune response may be required for recovery. Data also sug-
gest that a strong well regulated innate inflammatory response is
associated with a better outcome after EBOV infection (Baize
et al., 2002; Leroy et al., 2000). Antigen presenting cells such as
DCs and macrophages that act as a vital link between the early
innate and later adaptive immune response (Reis e Sousa, 2004)
serve as early targets of EBOV infection in vivo (Geisbert et al.,
2003) and likely play a prominent role in the pathogenesis of
EHF (Bray and Geisbert, 2005). These observations are thus
consistent with the idea that the earliest interactions of the
virus with the innate immune response influence the outcome of
disease.
Ebola virus-like particles (VLPs) have been used for the
study of early EBOV-host cell interactions. EBOV VLPs can be
generated by expression of VP40, the matrix protein of the
EBOV, and, co-expression of EBOV glycoprotein (GP) with
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et al., 2001; Timmins et al., 2001). In contrast to infection with
EBOV, Ebola VLPs comprised of VP40 and GP were
previously shown to stimulate both macrophages and DCs
(Bosio et al., 2004; Wahl-Jensen et al., 2005a), and based on this
capacity, the VLPs have been proposed as vaccines against
filoviruses (Warfield et al., 2003; Ye et al., 2006). Although it is
unclear how VLPs, which lack viral genetic material and
therefore cannot productively replicate, trigger this activation;
the interaction of Ebola VLPs with DCs will likely mimic the
initial interaction of DCs with infectious EBOV.
In this study, EBOV VLPs were employed to identify early
dendritic cell responses to virus infection. We have (1) carefully
characterized which VLP components contribute to the
activation and (2) defined the signaling pathways activated by
the VLPs. Our results suggest that VLPs are similar but not
identical to a prototypical activator of DCs, lipopolysaccharide
(LPS), in their capacity to induce cytokine production, activate
cellular transcription factors and to activate NF-κB and MAP
kinase signaling pathways. They also demonstrate that NF-κB
activation plays a critical role in both VLP and LPS induced DC
activation and that full activation of DCs requires that the GP on
the surface of the VLPs possess an intact carbohydrate-rich
mucin domain. These data therefore define mucin domain-
dependent signaling pathways that likely contribute to EBOV
pathogenesis.
Results
Incorporation of EBOV proteins into VLPs
In order to accurately define how VLPs affect DCs, we first
systematically characterized VLPs produced in 293T cells with
respect to their biochemical make-up and morphology. Over-
expression of the VP40 protein is sufficient to produce EBOV
VLPs which bud from transfected cells (Jasenosky et al., 2001;
Timmins et al., 2001). Moreover, co expression of additional
virus proteins such as GP, results in their incorporation into the
VLPs (Noda et al., 2002). We generated Ebola VLPs by
transfection of 293T cells with plasmids expressing VP40,
VP40 and GP or a combination of VP40, VP35, VP24, VP30,
NP and GP (“complete” or cVLP). Supernatants were
harvested from the mock or expression-plasmid transfected
293T cells, and the VLPs within the supernatant were purified
through a sucrose cushion, washed, resuspended and quanti-
tated for protein content. To determine their content and
morphological characteristics, purified VLPs were subjected
to western blotting, electron microscopy and silver staining
(Fig. 1).
When VLP samples were negative-stained and visualized
using an electron microscope, all samples, with the exception of
“mock” (not shown), demonstrated filamentous filovirus-like
morphology (Fig. 1A). Moreover, a representative example
shows that the VLPs are pleimorphic (Fig. 1B). Thus, the size
and morphological characteristics of the VLPs are similar to
those exhibited by EBOV (Geisbert and Jahrling, 1995).
Equivalent amounts of VLP protein, except for mock-trans-fected samples that contained little protein, were separated by
SDS-PAGE, blotted and examined using anti-VP40, VP24,
VP35, NP andGPmonoclonal antibodies. The presence of VP30
was not determined since specific antibodies against VP30 were
not readily available. VP40 was detected in all VLP preparations
(Fig. 1C). A ∼125 kDa form of GP was detected in VP40+GP
and cVLPs. VP35, VP24, and NP were detected in the VLPs
produced from the 293T cells transfected with a combination of
all proteins (cVLP), but not in the samples that contained only
VP40 or VP40+GP (Fig. 1C). The presence of GP in the VLPs
was also documented by silver staining (Figs. 1D and E),
electron microscopy, where VLPs appeared to a have GP-
decorated surface (data not shown), and by ELISA, using a
neutralizing monoclonal antibody against GP1 (KZ52; Mar-
uyama et al., 1999) (data not shown).
To determine the relative contribution of each EBOV protein
to the contents of the VLPs, VLPs produced from 293T cells
were analyzed by SDS PAGE and silver staining. Fig. 1D lane
cVLP shows the silver stained proteins from cVLPs. To identify
these proteins, individual components of the VLPs were
excluded from each transfection, with the exception of VP40
since it is required for efficient VLP production (Fig. 1D lanes-
GP, -NP, -VP35, -VP30, -VP24). The exclusion of GP produced
a silver stain that lacked a smear from 110–150 kDa (see lane-
GP) present in other lanes while exclusion of the NP protein
lacked the sharp band found at ∼105 kDa. This banding pattern
is consistent with the expected sizes of the glycosylated GP and
NP EBOV proteins (Fig. 1C), respectively. It is interesting to
note that bands appeared at approximately 35 kDa, but exclusion
of VP35 failed to eliminate these bands (Fig. 1D, lane-VP35).
Therefore, although VP24 and VP35 were present within VLPs
(Fig. 1C), their contribution to the final cVLP was minimal. In
Fig. 1E, VP40, VP40+GP VLPs were silver stained. A smear is
present in the VP40+GP VLP that corresponds to the expected
size of GP and a ∼40 kDa band is present in VP40 and VP40+
GP lanes (Fig. 1E) which would correspond to the expected size
of VP40.
VP40+GP VLPs are sufficient to efficiently stimulate DC
secretion of inflammatory cytokines IL-6, IL-8, TNFα, MIP-1α,
IL-12p40, RANTES and IP-10
Having demonstrated that VLPs containing different viral
components could be reproducibly generated, we next asked
whether different VLP preparations have different capacities to
stimulate DCs. Day 5–7 monocyte-derived immature DCs that
expressed no CD14, low MHCII, and high CD11c on their cell
surface (not shown) were used in these and subsequent
experiments. Equivalent protein concentrations of VLPs
(10 μg/mL) were added to DCs. We used 10 μg/mL of VLPs,
also used previously to stimulate DCs (Bosio et al., 2004),
because it was subsaturating for cytokine production (not shown).
Twenty-four hours post-treatment spent supernatant was tested
for the presence of IL-8, a marker of DC stimulation. As depicted
in Fig. 2A, DCs treated for 24 h with LPS (10 ng/mL), VP40+GP
and cVLPs, secreted similar levels of IL-8 (∼2000–2500 pg/mL)
while VP40 VLPs secreted less (∼400 pg/mL). This experiment
Fig. 1. Morphology and composition of VLPs. VLPs were prepared by expressing 1) VP40, 2) VP40 and GP and 3) VP40, VP24, VP35, VP30, NP and GP (cVLPs).
(A, B) VLPs were negatively stained and observed by electron microscopy. Shown in A is an example of VLP filovirus morphology. A representative VLP picture
shown in B) demonstrates the pleimorphic morphology of all the VLP preparations. All line bars represent a length of 500 nm. (C) Western blot analyses of purified
VLP preparations using antibodies against EBOV proteins GP, NP, VP40, VP35 and VP24. (D) Silver stains were performed on SDS-PAGE-separated purified VLPs.
The first lane, marked control, shows the contents of mock VLPs. In the second lane is an example of the proteins found in cVLPs. Each of the next lanes shows the
contents of cVLPs produced with exclusion of a single EBOV protein (protein excluded indicated above lane). Labeled arrows point to the indicated EBOV proteins.
(E) Shows silver stain of mock, VP40 and VP40+GP VLPs.
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supernatants were tested for the presence of both IL-8 and IL-6.
It should be noted that although the absolute amounts of
cytokine varied from experiment to experiment, possibly due to
differences in DCs derived from different donors, the trends
remained the same. These results are consistent with other
studies that demonstrated that VP40+GP VLPs could more
efficiently stimulate human DCs than VLPs that lacked GP
(Wahl-Jensen et al., 2005a; Ye et al., 2006). To exclude the
possibility that the VLPs were contaminated with LPS,
VP40+GP VLPs and LPS were boiled for 1 h. The resultingsamples were then used to stimulate DCs. In the case of
LPS, boiling did not inhibit or enhance LPS mediated DC
cytokine secretion (not shown). However, as previously
shown (Bosio et al., 2004), boiling of the Ebola VLPs
abolished their ability to stimulate DCs (not shown). These
results suggest that GP makes a major contribution to the
stimulatory function of the VLPs while no effect of the
internal components NP, VP35 and VP24 were detectable.
To further define the DC signaling pathways induced by
VLPs, the cytokine profiles in the supernatants of VLP stimu-
lated DCs were compared to the cytokine profile of a well
Fig. 2. VP40+GP VLPs are sufficient to efficiently stimulate DC secretion of inflammatory cytokines IL-6, IL-8, TNFα, MIP-1α, IL-12p40, RANTES and IP-10.
(A) Equivalent protein concentrations (10 μg/mL) of VP40, VP40+GP and cVLPs along with LPS (10 ng/mL) were added to DCs. Spent media, harvested 24 h
post-treatment, was tested for the presence of IL-8. (B) Mock, VP40+GP and LPS were used to stimulate DCs for 16–18 h. Spent supernatant was tested for the
presence of 22 cytokines listed in Table 1. A select number of cytokines are shown, including all cytokines present at levels >200 pg/mL from VLP-stimulated
DC supernatants.
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cytokines included in this multiplex analysis is provided in
Table 1. Those cytokines not highlighted in Table 1 were either
not detected or were detected below 200 pg/mL in the
supernatants of DCs stimulated with VLPs. Cytokines secreted
by DCs stimulated by VLPs (highlighted with bold text in Table
1) as well as those stimulated by LPS are shown in Fig. 2B.
VLP (VP40+GP)-stimulated DCs secreted IL-6, IL-8, MIP-
1α, RANTES and IP-10 at levels that were comparable to those
secreted by LPS-stimulated DCs (Fig. 2B). Although VP40+
GP VLPs stimulated many of the same cytokines as LPS,
TNFα, IL-12p40 and IL-10 were secreted at relatively higherTable 1
Cytokines detected in VLP-stimulated DC supernatants a
IL-1α IL-12p70
IL-1β IL-13
IL-2 IL-15
IL-3 GM-CSF
IL-4 IFN-γ
IL-5 TNFα
IL-6 EOTAXIN
IL-7 MCP-1 b
IL-8 RANTES
IL-10 MIP-1α
IL-12p40 IP-10
a VLP-stimulated DC supernatants were tested for the presence of the
cytokines shown in the table. Cytokines present at quantities above 200 pg/mL
shown in bold and in Fig. 2B.
b MCP-1 was present in supernatant of unstimulated DCs.levels by LPS-stimulated DCs. Nevertheless, the similar pattern
of cytokines secretion induced by LPS and VLPs suggested that
the two stimuli activate at least partially overlapping signaling
pathways.
VLPs induce IL-6 production through an NF-κB dependent
pathway
RANTES, TNFα, IL-6, MIP-1α and IL-8 are regulated by
the NF-κB signaling pathway (reviewed in Ali and Mann,
2004). Therefore, we compared the kinetics of induction of NF-
κB in DCs treated with VP40+GP VLPs (10 μg/mL), with LPS
(10 ng/mL) or with TNFα (50 ng/mL). Total dendritic cell
lysates were generated and subjected to Western blotting for
IκBα (Fig. 3A). NF-κB is held in the cytoplasm by IκB
proteins, including IκBα. Upon stimulation by ligands that
induce NF-κB via the classical pathway (for example by LPS or
TNFα), IκBα is phosphorylated and subsequently degraded
releasing NF-κB which translocates to the nucleus and activates
transcription of a variety of genes, including the IκBα gene. Fig.
3A shows that TNFα and LPS treatment of DCs induces IκBα
degradation within 10 min. However, VLP treatment induces a
significant decrease in IκBα levels only after 30 min. While the
LPS and VLP induced a reduction in IκBα that lasted at least up
to 1 h, the TNFα reduction in IκBα lasted up to 30 min, but
basal IkBα levels were restored by 1 h. This suggested that the
NF-κB activating signal induced by VLPs had different kinetics
than the NF-κB signal induced by LPS.
Table 2
Stimulated DC transcription factors a
TF binding Not
detected
Unchanged or
<2 fold change
Increased
(>2 fold)
Increased
(LPS only)
Transcription factors GATA EGR NF-κB Smad3/4
NFATc CREB E2F-1
SRE SP1 GRE
PRE PPAR NF-E1
IRF-1 RAR(DR5) USF-1
STAT-5 C/EBP Ets
Ets/PEA3 FAST-1
p53 NF-1
Myc-MaxC-Myb Pbx-1
GAS/ISRE STAT-1 b
TFIID STAT-3 b
AP-2 CBP c
STAT-6 d
SIE e
TR(DR4) e
STAT-4 f
a Shown in table is the relative induction of transcription factor binding after
LPS and VLP stimulation as compared to control (untreated DCs). Differences
in TF binding induction between LPS and VLP noted below table.
b STAT-1 and STAT-3 activity was detected after VLP and LPS treatment, but
was undetectable in unstimulated DCs.
c CBP activity was downregulated by VLPs after 10 min, but was upregulated
in LPS treated DCs.
d STAT-6 activity was upregulated by VLPs, but was only upregulated by LPS
after 30 min.
e Both SIE and TR(DR4) were upregulated by VLPs after 10 min, but at
30 min both were comparable to control.
f STAT-4 activity was upregulated by VLPs, but was only upregulated by LPS
after 30 min.
Fig. 3. VLPs induce IL-6 production through NF-κB. (A) DCs treated with
TNFα (50 ng/mL), LPS (10 ng/mL) and VP40+GP VLPs (10 μg/mL) for 10,
30, 60 and 120 min were harvested and total cell lysates (∼105 cellular
equivalents/lane) tested for the presence of IκBα and the loading control tubulin
by Western blotting. (B, C) DCs were pretreated for 15 min with SN50 NF-κB
inhibitor and control peptide and 1 h with IKK2 inhibitor. Then DCs were
treated with VLPs for 12–16 h and spent media tested for the presence of B) IL-6
and (C) lactate dehydrogenase. In (C) 100% represents the amount of lactate
dehydrogenase released into the media from DCs treated with 1% Triton X-100.
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the secretion of a representative cytokine (IL-6) that is
produced by VLP-stimulated DCs, DCs were pretreated with
NF-κB inhibitors prior to VLP addition (Figs. 3B and C). To
control for the NF-κB peptide inhibitor, a control peptide was
also used to pretreat the DCs. Supernatants from VLP
stimulated DCs were tested for the presence of IL-6 (Fig.
3B) or a marker of cell death, lactate dehydrogenase (Fig. 3C).
As shown in Figs. 3B and C, at concentrations that did not
have detectably toxic effects upon cells, the presence of
inhibitors but not control peptide profoundly inhibited IL-6
secretion. The peptide inhibitor of NF-κB interferes with NF-
κB nuclear translocation, while the IKK2 inhibitor inhibits
IKKβ, the upstream kinase that phosphorylates IκB. There-
fore, activation of the NF-κB signaling pathway contributes in
a critical way to VLP activation of DCs.VLPs activate numerous transcription factors
To further characterize the signaling pathways stimulated by
VLPs and LPS, transcription factors activated by either VLP or
LPS treatment at 10 and 30 min post-addition were identified.
Nuclear extracts were generated from harvestedDCs, and specific
transcription factors were detected using an array of DNA probes
(see Materials and methods). The strength of transcription factor
binding to its oligonucleotide target was then quantified. Signals
generated using the nuclear extracts from stimulated DCs were
compared to the signals generated by unstimulated DCs.
Transcription factor activities were compared, and if there was a
downregulation or upregulation of at least two fold, those trans-
cription factors were deemed to have been significantly altered.
By these criteria, a wide variety of transcription factors are
activated by VLPs within 10 min of stimulation and remain
activated through 30 min. Table 2 summarizes those transcrip-
tion factors that were active at both time points with the
exceptions stated in the notes. It is important to note that
transcription factors may show different strengths of activation
when comparing the two time points (10 and 30 min), but
because the results were not to be interpreted as being strictly
quantitative, this is not shown. VLPs were found by this method
to activate many of the same transcription factors as LPS.
Notably, this array further corroborates the activation of NF-κB
seen in Fig. 3. However, some differences between the VLP
and VLP-treated cells were noted. For example, Smad3/4
347O. Martinez et al. / Virology 364 (2007) 342–354was shown to be induced by LPS, but not by VLP stimulation
(Table 2).
VLPs induce MAPK ERK1/2 signaling
VLP stimulated transcription factors are involved in a variety
of processes that include inflammation (NF-κB), proliferation
(E2F-1), serum response and cell growth (SIE), hormone
response TR (DR4) and stress (Ets). Interestingly, MAPK
members phosphorylate and regulate members of the Ets
(Sharrocks, 2001), USF (Corre and Galibert, 2005) and STAT
(Decker and Kovarik, 2000) transcription factor families.
Therefore, we tested extracts of DCs stimulated 10, 30, 60
and 120 min with VLP and LPS for the presence of activated
ERK1/2, p38 and SAPK/JNK proteins, as evidenced by their
phosphorylation. As shown in Fig. 4, DCs stimulated with LPS
for 10 and 30 min showed ERK activation (as indicated by the
presence of phosphorylated ERK), while VLPs also induced
ERK phosphorylation, but with a different kinetics. ERK phos-
phorylation after VLP stimulation was seen after 30 min of
treatment. However, although activation of p38 and SAPK/JNKFig. 4. VLPs activate ERK1/2 in DCs. DCs treated with LPS (10 ng/mL) and
VLP (VP40+GP VLPs (10 μg/mL)) for 10, 30, 60 and 120 min were harvested
and total cell lysates (∼105 cellular equivalents/lane) were tested for the
presence of phosphorylated ERK1/2 (pERK1/2), total ERK1/2, phosphorylated-
p38 (pp38), total p38, phosphorylated-SAPK/JNK (pSAPK/JNK), total SAPK/
JNK and tubulin. The same membranes blotted and tested for pERK1/2, pp38
and pSAPK/JNK were stripped and tested for total levels of ERK1/2, p38 and
SAPK/JNK, respectively. The membrane Western blotted for SAPK/JNK was
stripped and tested for levels of tubulin.was seen after 30 min of LPS treatment, there was little p38 and
no SAPK/JNK phosphorylation seen in VLP stimulated DCs
(Fig. 4). Therefore, VLPs activate not only NF-κB but also ERK
signaling, following their addition to human DCs.
An intact GP mucin domain is required for DC activation
Expression of EBOV GP in human cells can have a profound
effect on the phenotype of that cell, and these effects are partly
due to the heavily glycosylated mucin domain located in the GP
ectodomain (e.g. Sullivan et al., 2005; Yang et al., 2000).
However, the mucin domain does not appear to be required for
GP to mediate cell attachment and entry (Jeffers et al., 2002;
Manicassamy et al., 2005; Yang et al., 2000). To test whether
the mucin domain was required for stimulation of DCs, a
mucin-deletion GP mutant (Δ309–476) was generated. First we
tested whether the GPΔmucin would be incorporated into
VLPs. 293T cells were mock, VP40, VP40+GP and VP40+
GPΔmucin transfected for 48 h and the presence of VLPs was
tested by Western blotting for VP40 after VLP purification.
Although mock contained no VP40 protein (see “mock” lane,
Fig. 5A), VP40 containing VLPs could be isolated from VP40,
VP40+GP and VP40+GPΔmucin transfected 293T super-
natants. Therefore, VLP production was not inhibited by the co-
expression of the GPΔmucin mutant. Furthermore, electron
microscopy performed on the VLPs demonstrated that VP40+
GPΔmucin VLPs had a similar morphology to VP40+GP
VLPs, including the appearance of a GP-decorated surface (not
shown). To test the level of GP incorporation into VLPs,
equivalent amounts of VP40, VP40+GP and VP40+ GPΔmu-
cin VLPs were subjected to an anti-GP ELISA (Fig. 5B). Mock
and VP40 VLPs show equivalent ODs while GP and
GPΔmucin containing VLPs demonstrate equivalent ODs.
Therefore, similar levels of WT and mutant GP are incorporated
into VLPs. Equivalent amounts of GP and GPΔmucin
containing VLPs were then used to stimulate DCs (along with
LPS control) for 10, 30, 60 and 120 min after which DCs were
harvested and lysates subjected to Western blot analysis for
ikappaBα, pERK1/2 and total ERK1/2 (Fig. 5C). The WT
VLPs, as previously shown in Fig. 5, induced ikappaBα
degradation at 30 and 60 min whereas a significant decrease in
ikappaB was not apparent in cells treated with the VP40+
GPΔmucin VLPs. Further, the moderate increase in ERK
phosphorylation was more apparent in the GP wild type
containing VLPs as compared to the mutant GP containing
VLPs (Fig. 5C). Densitometry analysis on the ikappaBα,
phospho ERK and control ERK bands within the Western blot
confirmed differences in the ratios of ikappaBa and phospho
ERK to total ERK between VLPGP and VLPGP Δmucin
treated DC lysates (not shown). Equivalent amounts of GP and
GPΔmucin containing VLPs were also used to stimulate DCs
(along with LPS control) for 20 h after which supernatants were
tested for the presence of IL-8 (Fig. 5D). As shown in Fig. 5D,
unstimulated DCs secreted relatively low levels of IL-8 similar
to those secreted by VLP+GP Δmucin treated DCs, while both
LPS and VLP+GP treated DCs secreted approximately 10 fold
more IL-8 than the unstimulated control. Finally, to confirm that
Fig. 5. VLP GP mucin domain-dependent activation of NFκB and ERK1/2. (A) Western blot analyses of purified VLP preparations using antibody against EBOV
protein VP40. (B) ELISA, performed on equivalent amounts of VP40, VP40+GP, VP40+GPΔmuc VLPs using an EBOV-neutralizing anti-GP antibody (AZ52). (C)
Shown is one blot of one representative experiment where equivalent protein concentrations (15 μg/mL) of VP40+GP and VP40+GPΔmuc VLPs and 10 ng/mL of
control LPS were used to treat DCs for 10, 30, 60 and 120 min and the total cell lysates (∼105 cellular equivalents/lane) were tested for the presence of IκBα,
phosphorylated ERK1/2 (pERK1/2) and total ERK1/2. (D) Shown is a representative experiment where equivalent protein concentrations (15 μg/mL) of VP40+GP
and VP40+GPΔmuc VLPs and 10 ng/mL of control LPS were used to treat DCs (5×105 cells) for 20 h and supernatant was tested for levels of IL-8. The control in this
experiment is unstimulated DCs (unstim). (E) Association of GFP-tagged VLPs with DCs was assayed by flow cytometry. Control (top left dot plot) depicts DCs
stained with isotype controls. Equivalent concentrations of (15 μg/mL) GFP-VP40+GP (bottom right dot plot), GFP-VP40+GPΔmuc (bottom left dot plot) and mock
VLPs purified from GFP-transfected cells (top right dot plot) were incubated with DCs for 30 min at 37 °C, washed, stained for the DC marker CD11c and assayed by
flow cytometry.
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to associate with DCs, we employed GFP-tagged VLPs. We
constructed and expressed a GFP-VP40 chimeric protein.
Expression of this stable (not shown) chimeric protein leads
to the production of fluorescent VLPs that can incorporate GPand can be visualized by fluorescence microscopy (not shown).
Equivalent (15 μg/mL) amounts of GFP-VP40+GP, GFP-
VP40+GPΔmuc and mock VLPs (purified from GFP-trans-
fected cells) were incubated with DCs for 30 min at 37 °C. Cells
were then washed and then tested for their association with
349O. Martinez et al. / Virology 364 (2007) 342–354VLPs by flow cytometry. Isotype controls showed no fluo-
rescence (Fig. 5E top left dot plot). CD11c+cells were
associated with equivalent GFP fluorescence when incubated
with GFP-VP40 +GP and GFP-VP40 +GPΔmuc VLPs
(Fig. 5E, bottom dot plots) but no GFP fluorescence was seen
when DCs were incubated with mock VLPs prepared from GFP
transfected 293Ts (Fig. 5E top right dot plot). Cumulatively,
these data demonstrate that the mucin domain of GP is not
required for association of VLPs with DCs but is required for
stimulation of DCs by the VLPs.
Discussion
Our data identify novel signals triggered by EBOV VLPs
within human DCs. These studies provide molecular context to
previous observations that EBOV VLPs activate DCs and
macrophages. These results also point to specific signaling
pathways that may be activated by the initial interaction of
EBOV with DCs and which may influence the outcome of
EBOV infection. Previous studies have demonstrated that
VP40+GP VLPs, but not VP40 VLPs could stimulate DCs
(Bosio et al., 2004; Ye et al., 2006). In our hands, VLPs
containing the viral matrix protein, VP40 and the viral
glycoprotein, GP, were found to induce a proinflammatory
response. The importance of GP for the DC response is expected,
and fits with its ability to induce a variety of cellular responses.
The EBOV GP is the viral attachment and fusion protein (Bar
et al., 2006; Feldmann et al., 2001), and it also exerts a variety of
additional effects upon cells, including surface protein modula-
tion (Simmons et al., 2002; Takada et al., 2000; Wahl-Jensen et
al., 2005b), induction of anoikis (Alazard-Dany et al., 2006; Ray
et al., 2004), and stimulation of cytokine production from human
macrophages (Wahl-Jensen et al., 2005a) and dendritic cells
(Bosio et al., 2004; Ye et al., 2006). Moreover, its vascular
cytotoxicity is thought to be play an important role in virulence
(Yang et al., 2000). In contrast, the presence of other viral
proteins; of which NP was the most abundant, did not
substantially alter DC responses. This observation is in spite
of the fact that other viral components might be expected to
modulate host cell responses to VLPs given their previously
described functions. For example, the VP35 and VP24 proteins
interfere with signaling pathways related to interferon responses
(Basler et al., 2000, 2003; Bosio et al., 2003; Hartman et al.,
2004; Reid et al., 2005, 2006). It remains unclear whether the
VP35 and VP24 in “complete” VLPs reflects an inability to
modulate DC responses when introduced into cells via VLPs or
their relatively low abundance in the VLPs.
VLPs containing the viral matrix protein (VP40) and the
viral glycoprotein (GP) were found to induce a proinflammatory
response highly similar to a prototypical DC activator, LPS.
This response included the production of several proinflamma-
tory cytokines, as measured by a multiplex cytokine assay.
Specifically, inflammatory cytokines IL-6, TNFα, and chemo-
kines IL-8, MIP-1α, RANTES and IP-10 are all secreted by
VP40+GP (Fig. 2) and cVLPs (not shown) stimulated DCs.
This is consistent with previous studies that demonstrated the
secretion of the above-mentioned cytokines (Bosio et al., 2004;Warfield et al., 2003; Ye et al., 2006) with the exception of IFN
protein-10 (IP-10), a protein which acts to attract activated
T cells and which plays a role in responses to viral infection
(Dufour et al., 2002). Additionally activation of NF-κB and
numerous other transcription factors (TFs) were demonstrated,
with a multiplex TF array, following either VLP or LPS
treatment of DCs. TFs activated by 10 min were, for the most
part, also stimulated after 30 min of VLP treatment (Table 2).
Therefore, the results of the 10 min array corroborated the
results of the 30 min array. This also showed that VLP treatment
induced rapid signaling. This raises the possibility that the
activation may be occurring shortly after interaction of the VLP
with receptors present at the plasma membrane of DCs. Further
studies are needed to clarify whether internalization of the VLPs
by the immature DCs is a requirement for DC stimulation. It is
interesting to note that NF-κB was activated (>2 fold change)
by VLPs, as compared to an unstimulated control, within
10 min of treatment (Table 2). However, in Fig. 3, IκBα
decreased significantly only after 30 min. The reason for this
seeming discrepancy is unclear, but may reflect the fact two
different parameters are being measured using two different
assays. Nevertheless, NF-κB was shown to be activated by
VLPs using two independent assays.
While the activation of NF-κB might have been predicted,
given the role of NF-κB in proinflammatory cytokine produc-
tion (Ali and Mann, 2004), it was important to demonstrate
experimentally that this activation plays a critical role in VLP
induced DC activation. This was addressed by employing
previously described NF-κB inhibitors. Specifically, IL-6
cytokine production was abolished when NF-κB inhibitors
SN50 and IKK2 inhibitors were used to pretreat DCs stimulated
with VLPs. The SN50 peptide inhibitor blocks NF-κB nuclear
translocation while IKK2 blocks IKKβ, a component of the
IKK kinase complex. Taken together, these data indicate that
VLPs induce IκBα degradation and that NF-κB activation is
important for IL-6 secretion.
Interestingly, the transcription factor array data also
suggested the activation of MAP kinase pathways. For example,
VLP-activated TFs included TFs that regulate cell cycle control
and apoptosis (EGR (Thiel and Cibelli, 2002), E2F-1 (Pardee
et al., 2004; Stevens and La Thangue, 2003)), stress and
inflammatory responses (NF-κB (Ali and Mann, 2004), Ets
(Sharrocks, 2001), STATs (Decker and Kovarik, 2000), USF-1
(Corre and Galibert, 2005), SIE (Wang et al., 2003)) and
mitogen and cytokine response (SIE, EGR (Decker et al., 2003),
STATs (Decker, 1999)). Of these, Ets, SIE, STAT and USF TF
family members can all be phosphorylated by the stress-induced
MAPKs. Consistent with the potential MAPK activated TFs
discovered through the array, we also demonstrated that VLPs
can significantly activate ERK1/2 (Fig. 4). However, unlike
LPS treatment, VLPs did not detectably activate p38 and SAPK/
JNK (Fig. 4). Although both LPS and VLP treatment activated
ERK1/2, they did so with different kinetics. As previously
demonstrated in a study showing the kinetics of LPS-stimulated
DC ERK1/2 activation (Ardeshna et al., 2000), ERK1/2
phosphorylation was maximal by 30 min while VLP treatment
induced ERK1/2 activation that lasted up to 1 h (Figs. 4 and 5).
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suggest that VLPs activate DCs in a manner that is similar but
not identical to the prototypical DC activator, LPS.
To further address the requirements for VP40+GP induced
DC activation, the role of the GP mucin domain in DC
activation was explored. As noted above, the heavily glycosy-
lated mucin domain is required for several cellular responses to
GP but is not required for GP-mediated cell attachment and
entry, at least for GP pseudotyped viruses (Jeffers et al., 2002;
Manicassamy et al., 2005; Yang et al., 2000). Although
GPΔmucin was incorporated into VLPs at levels similar to
GP, the VLPs containing GPΔmucin could not stimulate DC
iκBα degradation and ERK phosphorylation to the same extent
as VLPs containing wild type GP. The GPΔmucin VLPs also
failed to induce IL-8 production (Fig. 5). The fact that the
neutralizing antibody used in our ELISA (Fig. 5B) could bind
the GPΔmucin in the VLPs and the fact that both wild type GP-
VLPs and GPΔmucin-VLPs can associate with DCs to similar
levels (Fig. 5E) suggests that GPΔmucin is in a native confor-
mation and that VLPswithGPΔmucin can still infect cells. Since
both wild type and mutant VLPs could presumably mediate
virion entry, this would not explain the difference in signaling.
Further studies are required to understand how the mucin do-
main contributes to signaling leading to DC stimulation.
Although DC responses to LPS and VLPs were not identical,
many similarities were noted in our studies. It should also be
noted that it is difficult to exclude the possibility that a small
amount of contaminating LPS could play a role in the
stimulating capacity of our VLPs, however as previously
demonstrated (Bosio et al., 2004), VLPs, unlike LPS, lose their
stimulatory capacity when boiled (not shown). We also find that
the minimal values obtained in the limulus amebocyte lysates
assay employed to quantify endotoxin levels (<0.03 IU/μg total
protein, not shown and Fuller et al., 2006) were similar for
GPΔmucin VLPs as compared to GP VLPs (not shown).
Therefore endotoxin contamination cannot explain the differ-
ences seen between the two types of VLPs. Since LPS signals
through TLR4, it is tempting to speculate that VLPs may also
stimulate DCs through a TLR. However, GP interacts with a
variety of cell surface molecules. The identity of the primary
receptor(s) mediating EBOV entry is controversial (Simmons
et al., 2003b) and one cannot exclude signaling from this
receptor(s) as contributing to DC activation. In addition, GP can
interact with a variety of other molecules, including C-type
lectins, that are present upon DCs, monocytes and/or macro-
phages (Alvarez et al., 2002; Marzi et al., 2004; Mohamadzadeh
et al., 2006; Simmons et al., 2003a; Takada et al., 2004). Given
that the mucin domain is more glycosylated than other regions
of GP, it is intriguing to speculate that interactions between C-
type lectins and the mucin domain might contribute to signaling
within the DCs.
In conclusion, we show that within 1 h, EBOV GP-mediated
signaling leads to the activation of both NF-κB and ERK1/2,
and this response requires the presence of the GP mucin
domain. Previous studies suggest that EBOV infection of DCs
leads to poor pro-inflammatory cytokine production and DCs
that are not fully matured and fail to effectively activate a T cellresponse (Bosio et al., 2003; Mahanty et al., 2003). We
hypothesize that the signals activated by EBOV VLPs represent
signals that are also transduced by live EBOVand contribute to
the aberrant activation of DCs. Experiments are thus underway
to define the mechanism(s) by which these pathways are
activated by VLPs and to evaluate their significance in the
context of EBOV infection.
Materials and methods
Cells, plasmids and antibodies
293T (human embryonic kidney) cells were grown in
Dulbecco's modified Eagle's medium (DMEM; Invitrogen,
Carlsbad, CA) supplemented with 10% fetal calf serum
(Invitrogen), 2 mM L-glutamine (Invitrogen), 100 units/mL of
penicillin, 100 μg/mL streptomycin, 1 μg/mL ciproflaxocin at
37 °C in 7% CO2. All Ebola viral genes kindly provided by
Viktor Volchkov (INSERM, Lyon) and Elke Mühlberger
(Marburg University, Marburg) were sequenced and confirmed
to correspond to the published Zaire EBOV strain Mayinga
sequences. EBOV VP40 was expressed using the pCDNA3 or
pCAGGS vector while all the other EBOV proteins were
expressed using pCDNA3. The GPΔmucin gene was con-
structed as previously described (Manicassamy et al., 2005).
Antibodies used in these studies include anti-p38, -phosphop38,
-ERK1/2, -phosphoERK1/2, -SAPK/JNK, -phosphoSAPK/
JNK (cell signaling technology, Danvers, MA), anti-cd11c,
-CD14, -HLA-DR (BD Pharmingen, Franklin Lakes, NJ), anti-
VP40 was a kind gift from Ronald Harty (University of
Pennsylvania), anti-VP24 was a kind gift from Victor Volchkov
(INSERM), anti-VP35, anti-GP and anti-NP were developed in
collaboration with the Hybridoma Center located in the Mount
Sinai Department of Microbiology, neutralizing anti-GP1
(AZ52) was a kind gift from Erica Ollmann Saphire (The
Scripps Research Institute), anti-tubulin, anti-mouse, anti-
human and rabbit IgG (Sigma, St. Louis, MO), anti-IκBα
(Epitomics, Burlingame, CA).
VLP production
VLPs were produced by transfecting 3 μg of expression
plasmids into 1.5×106 293T cells in six-well dishes and by
transfecting 18 μg of expression plasmids into 107 293Ts in
10 cm plates. The EBOV Zaire VP40 expression plasmid was
transfected alone or in combinations with EBOV Zaire GP, NP,
VP24, VP30 and VP35 expression plasmids at equal DNA
concentrations. Furthermore, to visualize fluorescent VLPs, a
VP40-GFP (VP40 was cloned in frame at the N-terminus of
VP40) chimeric protein was expressed from the expression
plasmid pCAGGS. This protein could produce VLPs as
determined by Western blotting, fluorescent microscopy and
electron microscopy (not shown). Transfections were performed
using lipofectamine 2000 (Invitrogen) at a 1:1 ratio of DNA to
lipofectamine following the manufacturer's protocol. When
VLPs were produced for silver staining, media was replaced
12–16 h after 293T transfection with VP-serum free media
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were pelleted away from the harvested VLP-containing super-
natant with a cell spin. Then, VLPs were centrifuged through a
sucrose cushion at 26000 rpm in an SW-28 rotor for 2 h at 4 °C,
washed in ice-cold NTE buffer (10 mM Tris pH7.5, 100 mM
NaCl, 1 mM EDTA) by centrifuging at 26000 rpm for 2 h at
4 °C and then gently tapped 100 times to resuspend in 50–
100 μL of NTE buffer. VLP protein content was quantitated
using the DC protein assay (Bio-Rad, Hercules, CA). VLPs
were left on ice for up to 48 h until used. VLP preparations
contained <0.03 IU (endotoxin units) per microgram of total
protein as determined by the Limilus Amebocyte Lysate assay
(Cambrex, Walkersville, MD).
Electron microscopy
10 μL of VLPs were pipetted onto 300 mesh copper grid
coated with carbon film and incubated for 15 min at RT. Grids
were then washed twice with water and negatively stained for
15 s using 1% phosphotungstic acid buffered to pH 7.0 with 1 M
ammonium hydroxide. Particles were then visualized using a
Hitachi H7000 transmission electron microscope.
Silver staining
∼1 μg of serum-free VLPs (see VLP production) were
loaded onto 4–20% gradient gels and proteins were separated
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE). Silver staining was performed using SilverQuest
silver staining kit (Invitrogen) following the manufacturer's
protocol with the exception that half the reagent volumes were
used per assay.
Isolation and culture of human DCs
Peripheral blood mononuclear cells (PBMCs) were isolated
by Ficoll density gradient centrifugation (Histopaque; Sigma
Aldrich, St. Louis, MO) from buffy coats of healthy human
donors (New York Blood Center). CD14+ cells were immuno-
magnetically purified using anti-human CD14 antibody-labeled
magnetic beads and iron-based Midimacs LS columns (Miltenyi
Biotec, Auburn, CA). After elution from the columns, cells were
plated (0.7–1×106 cells/mL) in RPMI (Invitrogen, Carlsbad,
CA) supplemented with 2% human serum AB (GemCell,
Gemini Bio-Products, West Sacramento, CA), 100 units/mL of
penicillin, 100 μg/mL streptomycin, 55 μM β-mercaptoethanol,
500 U/mL human granulocyte–macrophage colony-stimulating
factor (GM-CSF; Peprotech, Rocky Hill, NJ), 500 U/mL human
interleukin-4 (IL-4; Peprotech), 1 μg/mL ciproflaxocin
(SIGMA) and incubated for 5 to 7 days at 37 °C.
Flow cytometry
Flow cytometry was performed in a Cytomic FC500
Coulter station (Beckman Coulter, Miami, FL). Data were
analyzed using WinMDI Version 2.8 (http://facs.scripps.edu/
software.html).DC stimulation
DCs plated in 96 well dishes (9×104 cells/well) or 24 well
dishes (0.5×106 cells/well) were stimulated with 10–20 μg/mL
VLP, 50 ng/mL TNFα or 10–100 ng/mL LPS (Salmonella
Minnesota R595; Alexis, San Diego, CA) for the indicated
amount of time in RPMI (Invitrogen, Carlsbad, CA) supple-
mented with 1% human serum AB (GemCell), 100 units/mL of
penicillin, 100 g/mL streptomycin, 55 μM β-mercaptoethanol.
Supernatants were tested for cytokine production, while har-
vested DCs were tested for MAPK and TF activation.
IL-6 and IL-8 ELISA
IL-6 and IL-8 was detected from supernatants collected 12–
24 h post stimulation using capture enzyme-linked immunosor-
bent assay (ELISA). The IL-6 and IL-8 (supernatant was diluted
1/10 prior to IL-8 ELISA) ELISAs were performed according to
the manufacturer's protocol (eBioscience, San Diego, CA and
BD Pharmingen, Franklin Lakes, NJ, respectively). Briefly for
the IL-6 ELISA, 96 well flat-bottomed Maxi-Sorp (Nunc,
Rochester, NY) plates were used for capture antibody coating
and subsequent IL-6 detection. Coated plates were washed three
times with PBS containing 0.05% Tween 20 (PBS-T) and
blockedwith PBS+10%FCS (PBS-F) at room temperature (RT)
for 1 h. Plates were washed three times with PBS-T, supernatants
added and incubated for 2 h at RT followed by five washes.
Detection and HRP conjugated streptavidin antibody incuba-
tions (1 h at RT) were separated by five washes. After a final
seven washes, TMB substrate was added to each well and
incubated for 15 min in the dark until the HRP reaction was
stopped with 1/4 volume of 1N HCl. Plates were read using an
ELISA plate reader (Biotek Instruments, Winooski, VT) at
450 nm wavelength.
GP ELISA
Mock VLPs and VLPs (with or without GP) were adsorbed
overnight onto Maxi-Sorp 96 well ELISA plates (Nunc) in
coating buffer (0.05 M carbonate–bicarbonate buffer, pH 9.6)
supplemented with 0.1% Triton X-100. Plates were washed
three times with PBS containing 0.05% Tween 20 (PBS-T) and
blocked with PBS+10% FCS (PBS-F) at RT for 1 h. Plates
were washed three times with PBS-T. Detection (AZ52 anti-GP
antibody) and HRP conjugated anti-human IgG antibody
incubations (1 h at RT) were separated by five washes. After
a final seven washes, TMB substrate was added to each well and
incubated for 15 min in the dark until the HRP reaction was
stopped with 1/4 volume of 1N HCl. Plates were read using an
ELISA plate reader (Biotek Instruments, Winooski, VT) at
450 nm wavelength.
NF-κB inhibition and cytotoxicity assays
DCs plated in 96 well dishes (9×104 cells/well) in RPMI
containing 1% human serum were pretreated 15 min with
inhibitor SN50 and control peptide SN50M at final
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IV) at a final concentration 2.5 μM (Calbiochem, EMD
Biosciences, San Diego, CA). Spent media from 1% Triton X-
100 or VLP-treated DCs (12–16 h) was tested for the presence
of IL-6 and lactate dehydrogenase. Amounts of lactate
dehydrogenase (LDH) were assayed using a Cytotoxicity
Detection Kit (LDH) (Roche, Basel, Switzerland) following
the manufacturer's protocol. 100% cytotoxicity was deter-
mined using the amount of LDH released into the media from
DCs treated with 1% Triton X-100.
Multiplex cytokine measurements
50 μL of the stimulated DC spent media was tested for the
presence of 22 human cytokines using Beadlyte Human 22-Plex
Multi-Cytokine Detection System (Upstate, Billerica, MA)
following the manufacturer's protocol. Plates were read in a
Luminex plate reader, and data were analyzed using software
from Applied Cytometry Systems (Sacramento, CA).
Nuclear extraction
Stimulated DCs were snap-frozen in a dry-ice ethanol bath.
Nuclear extractions were performed using nuclear extraction kit
(Panomics, Fremont, CA) following the manufacturer's proto-
col with the exception that the final resuspension volume was
30 μL. Protein content in nuclear extracts was then quantitated
using the DC protein assay (Bio-Rad).
Transcription factor array
Nuclear extractions (see above) were performed on untreated
DCs and DCs treated for 10 and 30 min with VLPs and LPS.
Equivalent nuclear protein concentrations (total of 7.5 μg) were
used in the Protein/DNA array I (Panomics, Fremont, CA) to
determine transcription factor (TF) activity following the
manufacturer's protocol. Very briefly, biotin-labeled probes
(TransSignal Probe Mix) were added to nuclear extracts and
incubated for 30 min at 15 °C. This allowed activated TFs to
bind probes forming a complex. After uncomplexed probes
were washed away using spin columns, the protein/DNA
complexes were disassociated. The column eluate containing
freed labeled probes was incubated with membranes spotted
with the probe complements. The hybridized spotted mem-
branes were then washed, incubated with streptavidin–HRPO,
washed again and developed by chemiluminescense. Each
transcription factor is represented by a pair of duplicate spots on
the array. One duplicate set being a dilution of the other set.
Arrays were developed using several exposure times in order to
avoid signal saturation. At each exposure, films of the arrays
were scanned and the intensity of spots quantitated using
ImageQuant software. The average signal of duplicate spots was
then obtained. If duplicate spots varied more than 25%, they
were eliminated from the analyses. In order to compare the
transcription factor signal from one membrane (sample) to the
control (untreated DCs), signals were normalized by dividing
the sample signal with the signal of an unchanged TF (selectedfrom that specific exposure). To be more stringent, signals were
normalized against two TFs. According to the manufacturer,>2
fold changes in signal are deemed to be significant. We chose to
deem significant those signals (i.e. NF-κB) that had a greater
than 2 fold difference as compared to the control when
normalized against both normalizing TFs. Moreover, almost
all transcription factors found to be activated at the 10 min mark
were also found to be significantly altered at the 30 min time
point as compared to control. Therefore, the 10 and 30 min
arrays reinforced the credibility of the transcription factors
found to be up or down-regulated. In a few exceptional cases,
TFs were upregulated at only one of the two time points, as
highlighted in Table 2.
Western blot
After the indicated time points of DC stimulation, 5×105
DCs/stimuli were harvested, pelleted and snap-frozen in a dry-
ice ethanol bath and stored at −80 °C. Cell pellets were
thawed on ice, resuspended in 50 μL of 1× protein sample
buffer, sonicated and loaded into a 4–20% gradient or 10%
gels for separation by SDS-PAGE. Proteins were transferred to
a polyvinylidene difluoride (PVDF) membrane, blocked in 1%
milk in TBS (50 mM Tris pH 7.5, 100 mM NaCl) for 1 h,
probed overnight with appropriate antibodies diluted in 0.5%
milk in TBS, washed 3 times in TBS-T (TBS+0.075%
Tween-20) for 5 min/wash, probed with secondary antibody
for 1 h and washed a final 3 times. The Western blots were
developed using the Western Lightning ECL kit (Perkin-
Elmer, Boston, MA) and Kodak BioMax film (Kodak,
Rochester, NY).
Flow cytometry
DCs were incubated with GFP-VP40 induced VLPs for
30 min at 37 °C and washed twice with PBS. Cells were then
stained with an anti-CD11c (Pharmingen) for 30 min at 0 °C and
washed again. FACS was performed using a Cytomics F500
machine (Beckman Coulter, Fullerton, CA) and then analyzed
using Win MDI 2.8 software.
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